Clinical trials results of a unique monoclonal antibody in asthma.
IgE binds to high affinity receptors (Fc epsilon RI) on mast cells, basophils, alveolar macrophages, and antigen-presenting cells. This results in the degranulation of effector cells and the release of mediators, such as histamine, leukotrienes, cytokines, that are causally linked to the pathophysiology of allergic asthma. It made for an attractive target for the development of a unique humanized monoclonal antibody, rhuMAb-E25 (E25). E25 offers a novel strategic approach to allergy treatment, it is expected that using E25 to significantly decrease IgE levels will result in improved control of allergic asthma.
Berger
W E
WE
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, CA, USA.
D000328:Adult; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000628:therapy*; D002452:Cell Count; D002648:Child; D004311:Double-Blind Method; D004804:Eosinophils; D005541:Forced Expiratory Volume; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007279:Injections, Subcutaneous; D051379:Mice; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012882:Skin Tests; D013183:Sputum / Q000166:cytology
D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins; C401983:rhuMAb-E25; D007073:Immunoglobulin E